Candel Therapeutics reports extended clinical benefits in phase 3 prostate cancer trial

May 15, 2026 4:05 PM

Candel Therapeutics, Inc. (NASDAQ: CADL) announced extended follow-up data from its phase 3 trial of aglatimagene besadenovec in localized prostate ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found